NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.4% – Here’s What Happened

Posted by Defense World Staff on Jan 14th, 2025

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Get Free Report) fell 0.4% during trading on Monday . The stock traded as low as $1.01 and last traded at $1.04. 102,508 shares were traded during trading, a decline of 17% from the average session volume of 124,001 shares. The stock had previously closed at $1.04.

Analyst Ratings Changes

Separately, Maxim Group reissued a “hold” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 16th.

Get Our Latest Research Report on NRSN

NeuroSense Therapeutics Stock Down 0.4 %

The stock has a fifty day moving average price of $1.12 and a 200-day moving average price of $1.06. The firm has a market cap of $14.16 million, a price-to-earnings ratio of -1.22 and a beta of 1.30.

NeuroSense Therapeutics (NASDAQ:NRSN – Get Free Report) last posted its quarterly earnings results on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

Hedge Funds Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. XTX Topco Ltd bought a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned approximately 0.24% of NeuroSense Therapeutics at the end of the most recent quarter. Institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

(Get Free Report)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.